Compare Amylx Pharmaceuticals Inc (AMLX) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Oxford Lane Capital Corp trades at $9.18 (market cap $891.54M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.2× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OXLC | |
|---|---|---|
Market Cap | $1.98B | $891.54M |
Sector | Health | Financials |
52-Week High | $18.70 | $20.80 |
52-Week Low | $7.64 | $8.15 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
OXLC trades at $9.13, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI readings. The company reported a net income margin exceeding 100% for 2025, yet recent quarterly earnings have consistently missed expectations, including a significant loss in Q1 2026. Dividend payments remain active, but negative ROE and ROA highlight financial strain. Analyst sentiment is divided, with a 50% buy rating amid concerns over net asset value declines and high distribution yields.
The outlook for OXLC is clouded by severe profitability challenges and volatile earnings, presenting high risk. While the dividend yield attracts income seekers, sustained NAV erosion and operational cash outflows signal underlying weakness. Investment opportunity hinges on a turnaround in CLO equity markets, but current fundamentals suggest caution is warranted for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
